Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $17.80

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) gapped up before the market opened on Wednesday . The stock had previously closed at $17.80, but opened at $18.43. Calliditas Therapeutics AB (publ) shares last traded at $18.36, with a volume of 1,530 shares traded.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Price Performance

The company has a quick ratio of 3.08, a current ratio of 3.13 and a debt-to-equity ratio of 2.89. The company has a market cap of $525.79 million, a PE ratio of -10.76 and a beta of 1.50. The stock has a 50-day simple moving average of $21.13 and a 200 day simple moving average of $20.57.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its earnings results on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. The company had revenue of $42.45 million for the quarter, compared to the consensus estimate of $36.24 million. During the same quarter in the previous year, the business earned ($0.01) earnings per share. Equities analysts expect that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Optiver Holding B.V. purchased a new stake in Calliditas Therapeutics AB (publ) in the fourth quarter valued at $25,000. Tower Research Capital LLC TRC raised its holdings in shares of Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after buying an additional 3,112 shares during the period. Jane Street Group LLC raised its holdings in shares of Calliditas Therapeutics AB (publ) by 7.6% in the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock valued at $191,000 after buying an additional 886 shares during the period. Finally, Deutsche Bank AG raised its holdings in shares of Calliditas Therapeutics AB (publ) by 26.5% in the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock valued at $2,170,000 after buying an additional 18,978 shares during the period. Hedge funds and other institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.